ArticleHeart rhythm O22022

Dose-limiting, adverse event-associated bradycardia with β-blocker treatment of atrial fibrillation in the GENETIC-AF trial.

William T Abraham et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.